{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:25:27Z","timestamp":1786119927006,"version":"build-2736575974"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1097\/01.asw.0000397898.56121.3f","type":"journal-article","created":{"date-parts":[[2011,4,19]],"date-time":"2011-04-19T06:26:24Z","timestamp":1303194384000},"page":"217-220","source":"Crossref","is-referenced-by-count":6,"title":["A Case of Refractory Pyoderma Gangrenosum Treated with a Combination of Apligraf and Systemic Immunosuppressive Agents"],"prefix":"10.1097","volume":"24","author":[{"given":"Giacomo","family":"Duchini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Itin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210202","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.rdc.2007.07.016","article-title":"Pyoderma gangrenosum: an update.","volume":"33","author":"Callen","year":"2007","journal-title":"Rheum Dis Clin North Am"},{"key":"R2-6-20210202","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0190-9622(88)70264-9","article-title":"Neutrophilic vascular reactions.","volume":"19","author":"Jorizzo","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"R3-6-20210202","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1610-0387.2007.0328.x","article-title":"Pyoderma gangrenosum: clinical presentation and outcome in 18 cases and review of the literature.","volume":"5","author":"Hasselmann","year":"2007","journal-title":"J Dtsch Dermatol Ges"},{"key":"R4-6-20210202","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00005792-200001000-00004","article-title":"Pyoderma gangrenosum: clinical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions.","volume":"79","author":"Bennett","year":"2000","journal-title":"Medicine (Baltimore)"},{"key":"R5-6-20210202","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaad.2004.10.006","article-title":"Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients.","volume":"53","author":"Reichrath","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"R6-6-20210202","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1365-2133.2003.05760.x","article-title":"Successful treatment of therapy-resistant chronic vegetating pyoderma gangrenosum with infliximab (chimeric antitumour necrosis factor antibody).","volume":"150","author":"Jenne","year":"2004","journal-title":"Br J Dermatol"},{"key":"R8-6-20210202","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2147\/ciia.2007.2.1.93","article-title":"A review of a bi-layered living cell treatment (Apligraf) in the treatment of venous leg ulcers and diabetic foot ulcers.","volume":"2","author":"Zaulyanov","year":"2007","journal-title":"Clin Interv Aging"},{"key":"R9-6-20210202","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archderm.138.8.1079","article-title":"The longevity of a bilayered skin substitute after application to venous ulcers.","volume":"138","author":"Phillips","year":"2002","journal-title":"Arch Dermatol"},{"key":"R10-6-20210202","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1743-6109.2006.00148.x","article-title":"Evaluation of Apligraf persistence and basement membrane restoration in donor site wounds: a pilot study.","volume":"14","author":"Hu","year":"2006","journal-title":"Wound Repair Regen"},{"key":"R11-6-20210202","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1097\/00007890-199906270-00014","article-title":"The allogeneic response to cultured human skin equivalent in the hu-PBL-SCID mouse model of skin rejection.","volume":"67","author":"Briscoe","year":"1999","journal-title":"Transplantation"},{"key":"R12-6-20210202","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1524-4725.1999.08186.x","article-title":"Acute excisional wounds treated with a tissue-engineered skin (Apligraf).","volume":"25","author":"Eaglstein","year":"1999","journal-title":"Dermatol Surg"},{"key":"R13-6-20210202","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1067\/mjd.2001.107962","article-title":"Accelerated healing of pyoderma gangrenosum treated with bioengineered skin and concomitant immunosuppression.","volume":"44","author":"de Imus","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"R14-6-20210202","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2337\/diacare.24.2.290","article-title":"Graftskin, a human skin equivalent, is effective in management of non-infected neuropathic diabetic foot ulcers.","volume":"24","author":"Veves","year":"2001","journal-title":"Diabetes Care"}],"container-title":["Advances in Skin &amp; Wound Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00129334-201105000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:30:37Z","timestamp":1786044637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00129334-201105000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/01.asw.0000397898.56121.3f","relation":{},"ISSN":["1527-7941"],"issn-type":[{"value":"1527-7941","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}